Sartorius Opens New Application Center in Shanghai
Sartorius has officially opened a new application center at its Shanghai office. Among the guests, representatives from the Shanghai government, customers from the biopharmaceutical industry, as well as business partners and the media, attended the opening ceremony.
With a floor space of 240 square meters, or 2600 square feet, the new application center offers ample room for product demonstrations, trial runs and training sessions. At this center, customers from the biopharmaceutical industry can now test the latest Sartorius products for cell cultivation, media and buffer preparation, sterile filtration, cross-flow purification, membrane chromatography, virus clearance and aseptic processing. For laboratory customers, Sartorius showcases its entire range of lab instruments and consumables from balances, moisture analysers, pipettes and water purification systems to filters and products for microbiological testing and quality control.
In his speech, Michael Melingo, member of the Sartorius Group Executive Committee and in charge of marketing, sales and services of Sartorius’ lab business, underlined the importance of Shanghai as a strategic and geographical hub for Sartorius in Asia. “Located close to our customers’ R&D centers in Shanghai and other biotech hotspots like Seoul, Tokyo and Singapore, our application center is the place to be for top scientists to talk about the latest industrial and technological trends.” With the substantial investment in this new application center, Sartorius has further extended its footprint in Asia.
Dr Jörg Lindenblatt, the Senior Vice President of Sales Asia/Pacific for Bioprocess Solutions, emphasised the practical approach of the application center. “Our application center is not just a showroom for our extensive range of lab and bioprocess products. We invite our customers to gain hands-on experience with our
technologies during training and demonstration. By doing this, we can demonstrate the benefits of the high degree of seamless integration of the newest state-of-the-art technology for biotech manufacturing.” Besides being used for demonstration purposes, the new application center will serve as training facility for customers,
distributors and staff.
Related News
-
News Women in Pharma: Moving beyond discussions and into best practice at CPHI Milan
In this second CPHI Milan special of our monthly series, we cover the key takeaways from the Diversity & Wellbeing track held on October 10, 2024. -
News AstraZeneca invests in AI collaboration for cancer drug trials
The British-Swedish pharmaceutical giant is partnering with biotechnology firm Immunai Inc to increase the efficiency of some cancer drug trials. -
News Ozempic and Wegovy prices questioned as Novo Nordisk faces US Senate hearing
The CEO of Novo Nordisk was grilled during a US Senate committee hearing on September 24, 2024, in which the exorbitant prices of the Danish company’s blockbuster drugs Ozempic and Wegovy were called into question. -
News The BIOSECURE Act: implications for the pharma supply chain
On September 9, 2024, the US House of Representatives voted to pass the bill titled the BIOSECURE Act (the Act), which lists several Chinese companies in the pharmaceutical supply chain. The Act will prohibit American companies from contracting or doin... -
News On Track at CPHI Milan: Thermo Fisher Scientific Track Sponsor interview
With CPHI Milan just around the corner, we sat down with some of the sponsors for this year’s conference tracks to discuss the most pressing topics in pharma. -
News CPHI Milan Speaker Spotlight: Pharma Manufacturing and Localisation in Africa
In the run-up to CPHI Milan, we sit down with some of the experts and thought-leaders speaking at this year’s conferences. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Eli Lilly licenses rheumatoid arthritis manufacturing in Africa
American pharmaceutical company Eli Lilly has signed a partnership with Egyptian organisation Eva Pharma to localise manufacturing of rheumatoid arthritis treatments in Africa.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance